Jeudi 3 décembre 2020 - 14:01 | A ne pas manquer : Le 10 Décembre 2020 - Réunion de la Banque centrale européenne

Isto technologies assumes full control of denovo et cartilage repair technology program

  • Publié le Lundi 29 avril 2013 à 14:30
  • Catégorie : ,
  • Source : Actusnews

Collaboration Agreement With Zimmer Holdings, Inc. Ended

ISTO to Proceed Independently With Phase III Clinical Trial

ST. LOUIS, April 29, 2013 (GLOBE NEWSWIRE) -- ISTO Technologies, Inc. announced today an agreement with Zimmer Holdings, Inc. whereby ISTO has assumed full control of the DeNovo® ET Engineered Tissue program, an engineered cartilage implant intended to repair cartilage defects in the knee. Under the terms of the agreement, any rights and responsibilities previously held by Zimmer related to ISTO and the program have been cancelled. ISTO has renamed the product RevaFlexTM and will proceed independently with further development of the program through a Phase III clinical program.

ISTO Technologies is committed to developing breakthrough products to regenerate and restore function to damaged cartilage and bone. As part of its cell-based orthobiologic platform, the company is currently involved in the development of two unique and potentially ground-breaking cell-based products intended to treat two of the leading causes of disability in the United States. In addition to RevaFlexTM, ISTO is developing NuQu®, a minimally-invasive early intervention treatment for discogenic back pain. The Company initiated Phase II clinical trials for NuQu in late December 2012. Both the RevaFlex and NuQu programs address significant unmet medical needs related to chronic pain and disability resulting from cartilage wear and degeneration problems that occur in the knee and lower back, respectively. ISTO's proprietary cell-expansion process provides the foundation for both programs. Through this process, allogeneic cells are expanded to create products capable of treating thousands of patients from a single donor, thus offering an economy of the scale and "off-the-shelf" therapeutic solution not possible with cartilage programs utilizing autologous cells.

In addition, under the terms of the termination of the collaboration agreement, ISTO will transfer ownership of DeNovo® NT, a particulated juvenile cartilage allograft tissue implant product, to Zimmer.

About ISTO
ISTO is a leading privately-held regenerative medicine company dedicated to improving patient quality of life through the development of proprietary products for spinal therapies and sport medicine applications. ISTO's products are intended for the repair and regeneration of damaged or injured cartilage and bone. For additional information on ISTO, please visit our website at www.istotech.com.

CONTACT: ISTO Technologies, Inc.
Scott Gill
Chief Financial Officer
(314) 995-6049

The Ruth Group
Nick Laudico (investors)
(646) 536-7030
nlaudico@theruthgroup.com

Lisa Cook (media)
(646) 536-7012
lcook@theruthgroup.com
 


Information non réglementée

Communiqué intégral et original au format PDF :
https://www.actusnews.com/documents_communiques/ACTUS-0-32072-ISTO.pdf
© Copyright Actusnews Wire
Recevez gratuitement par email les prochains communiqués de la société en vous inscrivant sur www.actusnews.com
Receive by email the next press releases of the company by registering on www.actusnews.com, it's free

Article précédent

CREDIT AGRICOLE SA : 1 md pour une croissance locale, durable et inclusive des territoires : le groupe Crédit Agricole réalise sa première émission d`obligations sociales

Ce contenu est diffusé par Hugin, il n`a qu`une portée informative et pédagogique.Les informations et données financières ainsi que les analyses diffusées par Hugin n`ont aucune valeur contractuelle et ne constituent en aucun cas une aide à la décision, une offre de vente ou une sollicitation d`achat de valeurs mobilières ou d`instruments financiers.

La responsabilité de LeGuideBoursier.com et/ou de ses dirigeants et salariés ne peut être retenue directement ou indirectement suite à l`utilisation des informations et analyses par les lecteurs et sur la pertinence des informations diffusées.

Il est recommandé à toute personne non avertie de consulter un conseiller professionnel avant tout investissement, car le trading peut vous exposer à des pertes supérieures aux dépôts chez votre broker.

Tout investisseur doit se faire son propre jugement avant d`investir dans un produit financier afin qu`il soit adapté à sa situation financière, fiscale et légale

Vous aimerez aussi